Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties (Q26866187)

Fabio Cenci

series ordinal

2

1 reference

language of work or name

1 reference

December 2011

1 reference

Tropical Medicine and International Health

published in

1 reference

volume

16

1 reference

issue

12

1 reference

page(s)

1466-73

1 reference

Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Piperaquine: a resurgent antimalarial drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Artemisinin Resistance in Plasmodium falciparum Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

A trial of combination antimalarial therapies in children from Papua New Guinea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Efficacy and safety of dihydroartemisinin-piperaquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Antimalarial therapies in children from Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Bisquinoline antimalarials: their role in malaria chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Determinants of in vitro drug susceptibility testing of Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X

Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02855.X